The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Study Overview
=================
Brief Summary
-----------------
This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital. Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.

Detailed Description
-----------------
The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria stated below, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 injection and the trig/glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. Triglyceride, glucose, and glycosylated hemoglobin values were checked at the beginning of the treatment and at the 3rd-month follow-up.

Official Title
-----------------
Investigation of the Triglyceride/Glucose Index in Diabetic Patients Using SGLT-2 Inhibitor

Conditions
-----------------
Metabolic Disease, Diabetes

Intervention / Treatment
-----------------
* Other: SGLT-2 inhibitors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 DM Age >18 years old Dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg 3 months follow-up period Exclusion Criteria: Type 1 diabetes Gestational diabetes Age < 18 years old Insufficient or missed laboratory test results Medical treatment for dyslipidemia Hypothyroidism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type 2 diabetic patients using SGLT-2 inhibitors<br>The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. | Other: SGLT-2 inhibitors<br>* This study is an observational study. It is not planned to do an interventional activity.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in triglyceride index | Decreased triglyceride index among patients using SGLT-2 inhibitors. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SGLT-2 inhibitor, triglyceride index